Pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has submitted the Unaudited Financial Results for the Quarter and Nine Months ended on 31st December, 2022 along with Limited Review Report.
The above information is a part of company’s filings submitted to BSE.